フルララネル標準品

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H360：生殖能または胎児への悪影響のおそれ

  H410：長期的影響により水生生物に非常に強い毒性

• 注意書き

  P201：使用前に取扱説明書を入手すること。

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P273：環境への放出を避けること。

  P281：指定された個人用保護具を使用すること。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

  P391：漏出物を回収すること。

  P405：施錠して保管すること。

  P501：内容物/容器を．．．に廃棄すること。

フルララネル標準品 価格

フルララネル標準品 化学特性,用途語,生産方法

• 効能

  外寄生生物駆除薬 (獣医薬)

• 説明

  Fluralaner (INN) is a systemic insecticide and acaricide that is administered orally. The U.S. Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014. The EU approved the drug in February 2014. Australia approved it for the treatment and prevention of ticks and fleas on dogs in January 2015.

• 使用

  Fluralaner(864731-61-3) is a novel systemically administered insecticidal and acaricidal compound that provides long-acting efficacy after oral administration to dogs. Fluralaner belongs to a new class of compounds, the isoxazolines. A field study has shown that a single fluralaner dose administered orally to dogs provides at least twelve weeks of flea- and tick-control. The long duration of activity offers a more convenient treatment over monthly flea and tick control treatments with a potential compliance advantage, reducing the risk of vector-transmitted diseases.

• 適応症

  Fluralaner is an insecticide and acaricide used to treat Sarcoptes scabiei var. canis infestation in dogs. Flea treatment. A possible anti-malarial found to kill disease-spreading mosquitoes when they bite treated people.

• 副作用

  Most pets have very few side effects from fluralaner, provided it is given according to label recommendations and at the prescribed interval (or for off-label use, according to your veterinarian's directions). Side effects may include vomiting, diarrhea, decreased appetite, or flaky skin.
  vcahospitals.com

• 過量投与

  No adverse reactions were observed following oral administration to puppies aged 8–9 weeks and weighing 2.0–3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (56 mg, 168 mg and 280 mg fluralaner/kg bodyweight) on three occasions at shorter intervals than recommended (8-week intervals).
  There were no findings on reproductive performance and no findings of concern on offspring viability when fluralaner was administered orally to Beagle dogs at overdoses of up to 3 times the maximum recommended dose (up to 168 mg/kg bodyweight of fluralaner).
  The veterinary medicinal product was well tolerated in Collies with a deficient multidrug-resistanceprotein 1 (MDR1 -/-) following single oral administration at 3 times the recommended dose (168 mg/kg bodyweight). No treatment-related clinical signs were observed.

• 薬物相互作用

  Fluralaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.
  During clinical field testing, no interactions between Bravecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.

• Mode of action

  Fluralaner is an inhibitor of the arthropod nervous system. It inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABAA receptors) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a related GABA-antagonist insecticide and acaricide).

フルララネル標準品 生産企業

Global(126)Suppliers

フルララネル標準品 スペクトルデータ(¹HNMR)

864731-61-3, フルララネル標準品 キーワード